<- Go Home
Aerovate Therapeutics, Inc.
As of April 28, 2025, Aerovate Therapeutics, Inc. was acquired by Jade Biosciences, Inc., in a reverse merger transaction. Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Market Cap
$77.7M
Volume
16.4K
Cash and Equivalents
$44.2M
EBITDA
-$53.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$884.98
52 Week Low
$43.75
Dividend
N/A
Price / Book Value
1.04
Price / Earnings
-1.58
Price / Tangible Book Value
1.04
Enterprise Value
$1.8M
Enterprise Value / EBITDA
-0.03
Operating Income
-$53.4M
Return on Equity
59.01%
Return on Assets
-36.18
Cash and Short Term Investments
$76.2M
Debt
$312.0K
Equity
$75.0M
Revenue
N/A
Unlevered FCF
-$35.0M
Sector
Biotechnology
Category
N/A